VRCA - NASDAQ

Verrica Pharmaceuticals Inc.

VRCA·NASDAQ

$6.10

+6.7%

HealthcareBiotechnology

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$64.99M

EPS-1.6800

P/E Ratio-3.63

Earnings Date08/11/2026

47.13M

Assets

-13%

3Y+5.0%

5Y-36.0%

10Y+8564.0%

22.39M

Total Liabilities

-65%

3Y+378.0%

5Y-46.0%

10Y+598.0%

24.74M

Total Equity

-351%

3Y-38.0%

5Y-25.0%

10Y-1029.0%

Verrica Pharmaceuticals Inc. Funding & Solvency Profile

VRCA · NASDAQ

Current Assets

Cash & Cash Equivalents30.15M

Net Receivables5.40M

Inventory2.24M

Other Current Assets4.76M

Total Current Assets43 M

Non-Current Assets

Property, Plant & Equipment1.86M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets2.73M

Total Non-Current Assets5 M

Total Assets

47.13M

Financial Health Analysis

Current Ratio

2.59x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.90x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

26 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

90% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Verrica Pharmaceuticals Inc. Balance Sheet

VRCA • NASDAQ

Verrica Pharmaceuticals Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	30.1M	46.3M	69.5M	34.3M	15.8M	10.7M	9.2M	10.3M	8.7M	527K
Short-Term Investments	0.0	0.0	0.0	0.0	54.6M	54.8M	52.8M	79.5M	0.0	0.0
Cash & Short-Term Investments	30.1M	46.3M	69.5M	34.3M	70.4M	65.5M	62M	89.8M	8.7M	527K
Net Receivables	5.4M	77K	4.4M	487K	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	5.4M	48K	4.2M	388K	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	29K	168K	99K	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	2.2M	2.5M	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	4M	2.2M	3M	1.3M	420K	17K
Other Current Assets	4.8M	2.3M	2.5M	4.4M	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	42.5M	51.2M	77.5M	39.1M	74.3M	67.7M	65M	91.2M	9.1M	544K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.9M	2.6M	3.6M	5.3M	5.5M	4.9M	2.2M	255K	0.0	0.0
Other Non-Current Assets	2.7M	376K	452K	276K	295K	1.6M	1.2M	499K	0.0	0.0
Total Non-Current Assets	4.6M	3M	4.1M	5.6M	5.8M	6.5M	3.4M	754K	0.0	0.0
Total Assets	47.1M	54.1M	81.6M	44.7M	80.1M	74.2M	68.4M	91.9M	9.1M	544K
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.1M	1.9M	2.5M	507K	845K	348K	1.2M	960K	167K	103K
Accounts Payable	2.1M	1.9M	2.5M	507K	845K	348K	1.2M	960K	167K	103K
Accrued Expenses	0.0	1.9M	4.8M	1.3M	1.6M	1.8M	841K	256K	400K	316K
Short Term Debt	746K	12.9M	0.0	0.0	41.7M	35.3M	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	667K	700K	297K	251K	198K	130K	0.0	0.0	0.0
Deferred Revenue	782K	0.0	0.0	0.0	0.0	500K	0.0	0.0	0.0	0.0
Other Current Liabilities	12.8M	11.6M	9M	1.4M	1.7M	1.3M	1.2M	1.3M	49K	0.0
Total Current Liabilities	16.4M	29M	17M	3.5M	46.1M	39.5M	3.4M	2.5M	616K	419K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	31M	42.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	5.1M	2.6M	0.0	0.0	0.0	0.0	0.0	0.0	15.5M	2.8M
Total Non-Current Liabilities	6M	35M	44.8M	1.2M	1.5M	1.7M	58K	0.0	15.5M	2.8M
Capital Lease Obligations	885K	2M	2.6M	1.5M	1.7M	1.9M	188K	0.0	0.0	0.0
Total Liabilities	22.4M	64M	61.8M	4.7M	47.5M	41.2M	3.4M	2.5M	16.1M	3.2M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8M
Common Stock	2K	9K	4K	4K	3K	3K	3K	3K	0.0	0.0
Additional Paid-In Capital	349.7M	297.2M	250.2M	203.5M	171.6M	136.9M	126.6M	122.5M	5.4M	12K
Retained Earnings	-324.9M	-307M	-230.4M	-163.5M	-139M	-103.9M	-61.2M	-33.1M	-12.4M	-2.7M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	-29K	1K	20K	-17K	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	-410K	0.0	0.0	-2.8M
Total Stockholders' Equity	24.7M	-9.9M	19.8M	40M	32.6M	33M	65M	89.4M	-7M	-2.7M
Total Equity	24.7M	-9.9M	19.8M	40M	32.6M	33M	65M	89.4M	-7M	-2.7M
SUMMARY
Total Liabilities & Equity	47.1M	54.1M	81.6M	44.7M	80.1M	74.2M	68.4M	91.9M	9.1M	544K
Total Investments	0.0	0.0	0.0	0.0	54.6M	54.8M	52.8M	79.5M	0.0	0.0
Total Debt	1.6M	45.9M	45.5M	1.5M	43.4M	37.2M	188K	0.0	0.0	0.0
Net Debt	-28.5M	-390K	-24M	-32.7M	27.7M	26.5M	-9.1M	-10.3M	-8.7M	-527K
Shares Outstanding	9,490,035	9,490,035	9,490,035	9,490,035	9,490,035	9,490,035	9,490,035	9,490,035	9,490,035	9,490,035

SEC Filings

VRCA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 20, 2026	June 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 11, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 11, 2026	March 11, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 30, 2025	December 23, 2025	2025	View Filing
S-3 S-3 N/A	December 15, 2025	December 15, 2025		View Filing
8-K 8-K 2025 N/A	November 24, 2025	November 23, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 14, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 154 filings

Related Guides

Blog Categories

Continue your VRCA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.